Figure 4: Inhibition of HAS as a new therapeutic suggestion.
From: Strategies of Mesenchymal Invasion of Patient-derived Brain Tumors: Microenvironmental Adaptation
(A) The inhibition of HAS genes in 4-methylumbelliferone (4-MU) treated GBM TSs within biomimetic environment after 72 hr invasion. 4-MU was treated after 12 hr invasion. Inset: 4-MU treated GBM TSs at 0 h. (B) Normalized proliferation of GBM in presence of 4-MU treatment in a fold-change. (A) Magnified immunofluorescent images for invaded GBM TSs in presence of 4-MU treatment. The 4-MU was treated at 12-hour after GBM invasion. Scale bar: 50 μm. (C) Molecular expression profiles in presence of 4-MU. (n = 5~6; Asterisks indicate a significant difference statistically by student’s t-test, *p < 0.05; **p < 0.01; ***p < 0.001).
